# SERENA-4 (NCT04711252)

> A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04711252
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: ER-Positive HER2-Negative Breast Cancer
- Interventions: AZD9833; Anastrozole; Anastrozole placebo; AZD9833 placebo; Palbociclib; Luteinizing hormone-releasing hormone (LHRH) agonist
- Enrollment: 1371
- Primary outcome: Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1

## Commentary we found

- YouTube: 42
- Podcasts: 32
- X threads: 15
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=serena-4-nct04711252

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04711252", "email": "<work email>"}; the inbox owner confirms by the emailed link.